Senesco starts transition from agbio to drug maker with first IND
This article was originally published in Scrip
Executive Summary
It's not every day that a company goes from creating a technology that extends the shelf life of bananas to using the same platform approach to try to prolong the lives of patients with multiple myeloma – a disease in which two-thirds of patients are dead within five years.